Data completeness
0/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ILOSONE SULFA is a pre-launch oral suspension combining erythromycin (macrolide antibiotic) with sulfonamide components, developed by Eli Lilly. The exact indications and mechanism are not yet public, but the formulation suggests activity against bacterial infections. This is a small-molecule antibiotic product positioned for oral delivery in pediatric or adult populations requiring suspension formulations.
Pre-Launch
Pre-launch stage indicates early-stage commercial planning with potential for small to mid-sized team build-out as regulatory milestones approach.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked jobs currently available, this pre-launch product represents a future opportunity as regulatory approval approaches. Career roles will initially focus on regulatory navigation, post-approval commercial planning, and medical affairs infrastructure build.
Regulatory Affairs SpecialistProduct Manager
Worked on ILOSONE SULFA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.